News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Curran Terrie
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/17/2023 |
4
| Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.|
Txns:
| Granted 200,000 shares
@ $0
Disposed/sold 175,000 options
@ $32.2, valued at
$5.6M
Disposed/sold 225,000 options
@ $39.11, valued at
$8.8M
|
|
| 06/02/2023 |
4
| Curran Terrie (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Granted 4,375 shares
@ $0
Granted 12,220 options to buy
@ $7.51, valued at
$91.8k
|
|
| 03/10/2023 |
4
| Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.|
Txns:
| Disposed/sold 3,673 shares
@ $0
Disposed/sold 33,846 options to buy
@ $11.3, valued at
$382.5k
Disposed/sold 11,154 options to buy
@ $12.68, valued at
$141.4k
Disposed/sold 22,500 options to buy
@ $13.14, valued at
$295.7k
Disposed/sold 22,500 options to buy
@ $24.25, valued at
$545.6k
Disposed/sold 5,250 options to buy
@ $7.65, valued at
$40.2k
Disposed/sold 21,603 options to buy
@ $21.47, valued at
$463.8k
Disposed/sold 21,096 options to buy
@ $22.71, valued at
$479.1k
|
|
| 01/20/2023 |
4
| Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.|
Txns:
| Granted 97,500 shares
@ $0
Sold 5,821 shares
@ $8.1995, valued at
$47.7k
Granted 162,500 options to buy
@ $8.35, valued at
$1.4M
|
|
| 11/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/02/2022 |
4
| Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.|
Txns:
| Granted 7,500 shares
@ $0 |
|
| 06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/11/2022 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 01/21/2022 |
4
| Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.|
Txns:
| Granted 41,250 shares
@ $0
Granted 206,250 options to buy
@ $15.21, valued at
$3.1M
|
|
| 11/09/2021 |
4
| Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.|
Txns:
| Granted 21,096 options to buy
@ $22.71, valued at
$479.1k
|
|
| 09/13/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/29/2021 |
4
| Curran Terrie (President and Chief Executive) has filed a Form 4 on Phathom Pharmaceuticals, Inc.|
Txns:
| Granted 225,000 options to buy
@ $39.11, valued at
$8.8M
|
|
| 11/04/2020 |
4
| Curran Terrie (Director) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Granted 37,500 options to buy
@ $18.72, valued at
$702k
|
|
| 11/04/2020 |
3
| Curran Terrie (Director) has filed a Form 3 on Arcutis Biotherapeutics, Inc. |
| 09/17/2020 |
4
| Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.|
Txns:
| Granted 21,603 options to buy
@ $21.47, valued at
$463.8k
|
|
| 07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/22/2019 |
4
| Curran Terrie (PRES., GLBL INFLAM. AND IMMUN.) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Disposed/sold 3,426 restricted stock units
@ $0
Disposed/sold 1,857 restricted stock units
@ $0
Disposed/sold 6,593 restricted stock units
@ $0
Disposed/sold 4,120 restricted stock units
@ $0
Disposed/sold 27,749 restricted stock units
@ $0 |
|
| 11/22/2019 |
4
| Curran Terrie (PRES., GLBL INFLAM. AND IMMUN.) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 5,139 shares
@ $0
Granted 9,889 shares
@ $0
Granted 17,840 shares
@ $0
Disposed/sold 37,181 shares
@ $0
Disposed/sold 327 shares
@ $0
Disposed/sold 5,500 options to buy
@ $58.33, valued at
$320.8k
Disposed/sold 3,750 options to buy
@ $81.56, valued at
$305.9k
Disposed/sold 7,500 options to buy
@ $87.64, valued at
$657.3k
Disposed/sold 5,000 options to buy
@ $103.1, valued at
$515.5k
Disposed/sold 7,050 options to buy
@ $117.18, valued at
$826.1k
Disposed/sold 5,000 options to buy
@ $118.57, valued at
$592.9k
|
|
| 10/24/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 09/19/2019 |
4
| Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Sold 4,500 shares
@ $98.2, valued at
$441.9k
Sold 6,838 shares
@ $98.31, valued at
$672.2k
Exercised 4,500 options to buy
@ $58.33, valued at
$262.5k
|
|
| 08/27/2019 |
4
| Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.|
Txns:
| Granted 58,608 options to buy
@ $7.65, valued at
$448.4k
|
|
| 05/06/2019 |
4
| Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Paid exercise price by delivering 490 shares
@ $95.21, valued at
$46.7k
Exercised 1,563 restricted stock units
@ $0 |
|
| 03/05/2019 |
4
| Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 27,749 restricted stock units
@ $0 |
|
| 02/06/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/18/2018 |
4
| Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Paid exercise price by delivering 1,231 shares
@ $68.2, valued at
$84k
Exercised 2,500 restricted stock units
@ $0 |
|
| 10/31/2018 |
4
| Curran Terrie (SEE REMARKS) has filed a Form 4 on CELGENE CORP /DE/|
Txns:
| Granted 12,983 options to buy
@ $71.43, valued at
$927.4k
|
|
| 09/04/2018 |
4
| Curran Terrie (Director) has filed a Form 4 on Myovant Sciences Ltd.|
Txns:
| Granted 22,500 options to buy
@ $24.25, valued at
$545.6k
|
|
| 05/17/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|